drugset / Trial / NCT07162883
Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary purpose of this study is to demonstrate Pharmacokinetic similarity in exposure after the initial dose and at steady state of QL2107 compared with Keytruda.
Timeline
- Start
- 2025-09-01
- Primary completion
- 2026-12-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | QL2107 | Unknown | 200 mg | Intravenous |